Howard A Burris MD

Clinical Trials

• Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer Start of enrollment: 2001 Apr 01

  Terminated

  Phase 2

• Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer Start of enrollment: 2000 Nov 01

  Completed

  Phase 2

• Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors Start of enrollment: 2002 Feb 01

  Completed

  Phase 1

• Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors Start of enrollment: 2003 May 01

  Completed

  Phase 1

• A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors Start of enrollment: 2006 Jan 01

  Suspended

  Phase 1

• Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies Start of enrollment: 2006 Mar 01

  Completed

  Phase 1

• Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors Start of enrollment: 2006 Sep 01

  Completed

  Phase 1

• A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors Start of enrollment: 2006 Jul 01

  Completed

  Phase 1

• A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors Start of enrollment: 2007 Jun 01

  Completed

  Phase 1

• Study of NK012 in Patients With Refractory Solid Tumors Start of enrollment: 2007 Mar 01

  Completed

  Phase 1

• LBH589 and Gemcitabine in the Treatment of Solid Tumors Start of enrollment: 2007 Nov 01

  Terminated

  Phase 1

• LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors Start of enrollment: 2007 Dec 01

  Completed

  Phase 1

• Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer Start of enrollment: 2007 Jun 01

  Completed

  Phase 1

• Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors Start of enrollment: 2008 Jan 01

  Terminated

  Phase 1

• PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies Start of enrollment: 2004 Oct 01

  Completed

  Phase 1

• A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer Start of enrollment: 2006 Dec 21

  Completed

  Phase 1

• LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients Start of enrollment: 2008 May 01

  Completed

  Phase 1

• SCRI Tissue Testing Registry Start of enrollment: 2010 May 01

  Terminated

• Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer Start of enrollment: 2010 Jul 01

  Completed

  Phase 1

• Safety Study of MGA271 in Refractory Cancer Start of enrollment: 2011 Jul 01

  Completed

  Phase 1

• A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01

  Completed

  Phase 1

• Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma Start of enrollment: 2011 Oct 01

  Completed

  Phase 1, Phase 2

• Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer Start of enrollment: 2012 May 01

  Completed

  Phase 1

• Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Jan 07

  Completed

  Phase 1

• Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01

  Completed

  Phase 1, Phase 2

• Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Start of enrollment: 2013 Jul 01

  Completed

  Phase 1, Phase 2

• Tissue Procurement Substudy for Participants in Study CP-MGA271-01 Start of enrollment: 2013 Jul 01

  Terminated

  Phase 1

• Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma Start of enrollment: 2013 Nov 01

  Terminated

  Phase 1

• Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors Start of enrollment: 2014 May 01

  Completed

  Phase 1

• Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Start of enrollment: 2016 Sep 28

  Completed

  Phase 2

• A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23

  Terminated

  Phase 1

• Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors Start of enrollment: 2017 Dec 31

  Unknown status

  Phase 1

  Roles: Contact

• CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma Start of enrollment: 2018 Feb 15

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

  Roles: Principal Investigator, Contact

• CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) Start of enrollment: 2018 Jun 27

  COMPLETED

  PHASE1, PHASE2

  Roles: Contact, Principal Investigator

• Join now to see all